ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
DHT Gel Effectively Treats Gynecomastia in HIV + Men
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 125442" data-attributes="member: 3"><p><span style="font-size: 15px"><strong>Dihydrotestosterone Administration Does Not Increase Intraprostatic Androgen Concentrations or Alter Prostate Androgen Action in Healthy Men: A Randomized-Controlled Trial</strong></span></p><p></p><p>J Clin Endocrinol Metab. 2011 Feb; 96(2): 430–437. </p><p></p><p><span style="font-size: 22px"><strong>abstract</strong></span></p><p>Context:</p><p>Concern exists that androgen treatment might adversely impact prostate health in older men. Dihydrotestosterone (DHT), derived from local conversion of testosterone to DHT by 5α-reductase enzymes, is the principal androgen within the prostate. Exogenous androgens raise serum DHT concentrations, but their effects on the prostate are not clear.</p><p></p><p>Objective:</p><p>To determine the impact of large increases in serum DHT concentrations on intraprostatic androgen concentrations and androgen action within the prostate.</p><p></p><p>Design:</p><p>Double-blind, randomized, placebo-controlled.</p><p></p><p></p><p>Participants:</p><p>31 healthy men ages 35–55.</p><p></p><p>Intervention:</p><p>Daily transdermal DHT or placebo gel.</p><p></p><p>Main Outcome Measures:</p><p>Serum and prostate tissue androgen concentrations and prostate epithelial cell gene expression after 4 wk of treatment.</p><p></p><p>Results:</p><p>Twenty-seven men completed all study procedures. <strong>Serum DHT levels increased nearly sevenfold, while testosterone levels decreased in men treated with daily transdermal DHT gel but were unchanged in the placebo-treated group (<em>P</em> < 0.01 between groups). In contrast, intraprostatic DHT and testosterone concentrations on d 28 were not different between groups (DHT: placebo = 2.8 ± 0.2 <em>vs.</em> DHT gel = 3.1 ± 0.5 ng/g; T: placebo = 0.6 ± 0.2 <em>vs.</em> DHT gel = 0.4 ± 0.1, mean ± SE). Similarly, prostate volume, prostate-specific antigen, epithelial cell proliferation, and androgen-regulated gene expression were not different between groups.</strong></p><p></p><p>Conclusions:</p><p>Robust supraphysiologic increases in serum DHT, associated with decreased serum T, do not significantly alter intraprostatic levels of DHT, testosterone, or prostate epithelial cell androgen–regulated gene expression in healthy men. Changes in circulating androgen concentrations are not necessarily mimicked within the prostate microenvironment, a finding with implications for understanding the impact of androgen therapies in men.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 125442, member: 3"] [SIZE=15px][B]Dihydrotestosterone Administration Does Not Increase Intraprostatic Androgen Concentrations or Alter Prostate Androgen Action in Healthy Men: A Randomized-Controlled Trial[/B][/SIZE] J Clin Endocrinol Metab. 2011 Feb; 96(2): 430–437. [SIZE=22px][B]abstract[/B][/SIZE] Context: Concern exists that androgen treatment might adversely impact prostate health in older men. Dihydrotestosterone (DHT), derived from local conversion of testosterone to DHT by 5α-reductase enzymes, is the principal androgen within the prostate. Exogenous androgens raise serum DHT concentrations, but their effects on the prostate are not clear. Objective: To determine the impact of large increases in serum DHT concentrations on intraprostatic androgen concentrations and androgen action within the prostate. Design: Double-blind, randomized, placebo-controlled. Participants: 31 healthy men ages 35–55. Intervention: Daily transdermal DHT or placebo gel. Main Outcome Measures: Serum and prostate tissue androgen concentrations and prostate epithelial cell gene expression after 4 wk of treatment. Results: Twenty-seven men completed all study procedures. [B]Serum DHT levels increased nearly sevenfold, while testosterone levels decreased in men treated with daily transdermal DHT gel but were unchanged in the placebo-treated group ([I]P[/I] < 0.01 between groups). In contrast, intraprostatic DHT and testosterone concentrations on d 28 were not different between groups (DHT: placebo = 2.8 ± 0.2 [I]vs.[/I] DHT gel = 3.1 ± 0.5 ng/g; T: placebo = 0.6 ± 0.2 [I]vs.[/I] DHT gel = 0.4 ± 0.1, mean ± SE). Similarly, prostate volume, prostate-specific antigen, epithelial cell proliferation, and androgen-regulated gene expression were not different between groups.[/B] Conclusions: Robust supraphysiologic increases in serum DHT, associated with decreased serum T, do not significantly alter intraprostatic levels of DHT, testosterone, or prostate epithelial cell androgen–regulated gene expression in healthy men. Changes in circulating androgen concentrations are not necessarily mimicked within the prostate microenvironment, a finding with implications for understanding the impact of androgen therapies in men. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
DHT Gel Effectively Treats Gynecomastia in HIV + Men
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top